CorestemChemon Partners with ATG Lifetech to Advance Organoid-Based Preclinical Testing
核心洞察
CorestemChemon (搜索), a GLP-certified preclinical CRO from South Korea, has formed a strategic partnership with ATG Lifetech (搜索) to deliver transcriptomics-powered, organoid-based preclinical testing services globally.
The collaboration will develop disease-relevant organoid models for liver (搜索), heart (搜索), and blood-brain barrier (搜索) applications, offering up to 5x greater predictive accuracy compared to conventional 2D cell cultures.
The partnership aims to provide high-throughput transcriptomics analytics for tumorigenicity studies and regulatory-aligned expertise for FDA/EMA pathways across the US, Europe, and Asia.
CorestemChemon (搜索), a leading GLP-certified preclinical contract research organization (CRO) based in South Korea, has announced a strategic partnership with ATG Lifetech (搜索), a biotechnology startup specializing in transcriptome analytics and organoid-based modeling. The collaboration aims to deliver next-generation, precision-driven non-clinical solutions to pharmaceutical companies and biotech ventures across the US, Europe, and Asia.
Advanced Platform Development
Through this partnership, the two companies will co-develop several innovative platforms designed to enhance drug discovery and development processes. The collaboration will focus on creating a transcriptome-based evaluation platform for predictive drug efficacy and safety profiling, alongside disease-relevant organoid models for liver (搜索), heart (搜索), and the blood-brain barrier (搜索) (BBB).
The partnership will also establish a high-throughput transcriptomics analytics service specifically designed for differentiating true versus false positives in tumorigenicity studies. Additionally, both companies will provide shared access to regulatory-aligned expertise for global clients targeting FDA and EMA pathways.
Enhanced Predictive Accuracy
Organoid-based assays are increasingly recognized for their translational advantage, offering up to 5x greater predictive accuracy in toxicity and efficacy screening compared to conventional 2D cell cultures, according to industry benchmarks. When integrated with whole-transcriptome analysis, these platforms enable earlier go/no-go decisions in drug pipelines, helping clients de-risk clinical entry and reduce overall development timelines.
"ATG Lifetech (搜索)'s disruptive transcriptome and organoid platforms will significantly elevate the scientific fidelity of our preclinical services," said a CorestemChemon (搜索) spokesperson. "This alliance positions us to compete as a global CRO partner offering best-in-class biological relevance and regulatory readiness."
Strategic Growth and Market Expansion
The partnership directly supports CorestemChemon (搜索)'s strategic growth plan to expand high-margin, IP-driven CRO services globally. Revenue-generating service offerings are expected to begin rolling out by late 2025, with significant global demand already projected.
ATG Lifetech (搜索) brings validated expertise from its international collaborations, including with ACROBiosystems (搜索) (Switzerland), and has been selected as a core developer in several South Korean government-backed biopharma initiatives.
Future Milestones
The two companies plan to showcase their joint research outputs at a major toxicology and preclinical science conference in Q4 2025. Global service launches will follow, focused on biotech and pharmaceutical customers in need of high-content, biologically faithful preclinical testing.
CorestemChemon (搜索) (KOSDAQ: 166480) is a full-service preclinical CRO with over two decades of experience in GLP-based toxicology, pharmacokinetics, and regulatory compliance. The company operates multiple AAALAC-certified facilities and partners with leading biopharmaceutical innovators across Asia, the US, and Europe.